Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZS-1003
- Development stage
- Preclinical
- Lead developer
- Genuine Biotech
- Modality
- Small Molecules
01
Overview
ZS-1003 (also known as ZSSW-136) is a novel small-molecule topoisomerase I (TOPO1) inhibitor developed by Bio Genuine (Genuine Biotech). Discovered through an AI-Computer Assisted Drug Design (CADD) approach, the compound features a unique parent nucleus structure that differentiates it from traditional camptothecin-based drugs. This structural modification is designed to overcome drug resistance mechanisms associated with existing TOPO1 inhibitors, such as those found in irinotecan-resistant tumors. ZS-1003 is being developed for the treatment of various solid and malignant tumors, demonstrating significantly higher potency in resistant cancer cell lines compared to conventional payloads.
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on ZS-1003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZS-1003.